Jpmorgan Chase & CO Ikena Oncology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 849 shares of IKNA stock, worth $1,460. This represents 0.0% of its overall portfolio holdings.
Number of Shares
849
Previous 13,341
93.64%
Holding current value
$1,460
Previous $18,000
94.44%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding IKNA
# of Institutions
72Shares Held
31.4MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$8.63 Million1.1% of portfolio
-
Bvf Inc San Francisco, CA4.77MShares$8.2 Million0.24% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$7.04 Million2.8% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$6.09 Million0.14% of portfolio
-
Omega Fund Management, LLC Boston, MA2.25MShares$3.87 Million4.84% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $62.4M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...